Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.46 |
| ▸ | CA1 | P00915 | 5/20 | 0.46 |
| ▸ | TMPRSS15 | P98073 | 8/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6434983 | 1.00 | CA2 (0.46) | CA2CA1TMPRSS15PRSS1MRGPRX4 | |
| SCHEMBL7370211 | 0.94 | CA2 (0.51) | CA2CA1TMPRSS15PRSS1CASP3 | |
| Trifluoroacetic Acid SCHEMBL6434379 | 0.92 | CA2 (0.46) | CA2CA1TMPRSS15MRGPRX4PDK1 | |
| Trifluoroacetic Acid SCHEMBL6432682 | 0.89 | CA2 (0.49) | CA2CA1MRGPRX4PDK1PDK2 | |
| Trifluoroacetic Acid SCHEMBL6432685 | 0.89 | CA2 (0.49) | CA2CA1MRGPRX4PDK1PDK2 | |
| Trifluoroacetic Acid SCHEMBL6435197 | 0.89 | GRN (0.51) | CA2CA1TMPRSS15ITGB3ITGA2B | |
| Trifluoroacetic Acid SCHEMBL6435207 | 0.89 | GRN (0.51) | CA2CA1TMPRSS15ITGB3ITGA2B | |
| Trifluoroacetic Acid SCHEMBL6434862 | 0.87 | CTSA (0.42) | ITGB3ITGA2B | |
| SCHEMBL6434387 | 0.86 | MRGPRX4 (0.37) | CA2CA1TMPRSS15MRGPRX4PDK1 | |
| Trifluoroacetic Acid SCHEMBL6437718 | 0.84 | CA2 (0.45) | CA2CA1MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026836-A1 | Composition for the treatment of damaged tissue | DACK KEVIN NEIL (GB) | 2005-02-03 | — | — | US | disclosed |
| US-20030199440-A1 | Composition for the treatment of damaged tissue | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
| EP-1077945-B1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-1242120-A2 | COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE | Pfizer Limited (GB) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001049309-A2 | COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE | PFIZER LIMITED (GB) | 2001-07-12 | — | — | WO | disclosed |
| US-6093731-A | Isoquinolines | PFIZER INC. | 2000-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199440-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | CA2 3285/4885CA1 3943/4885TMPRSS15 142/4885 |
| US-20050026836-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | CA2 3285/4885CA1 3943/4885TMPRSS15 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.